Document is current
Any future updates will be listed below
-
Authors
Deng, Jie https://orcid.org/0000-0002-1048-8762
Golub, Lorne M.
Lee, Hsi-Ming
Bhatt, Heta-Dinesh
Johnson, Francis
Xu, Tian-min
Gu, Ying
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (82201063; 82071172)
National Natural Science Foundation of China (82201063; 82071172)
Research Foundation for the State University of New York (1050308)
Research Foundation for the State University of New York (1050308)
Research Foundation for the State University of New York (1050308)
Research Foundation for the State University of New York (1050308)
National Key Clinical Specialty Construction Project (PKUSSNMP-201902)
- License Information
-
More Information
Article History
Received: 23 January 2023
Accepted: 15 September 2023
First Online: 19 September 2023
Competing interests
: LM Golub is listed as an inventor on several related patents, including CMC2.24, and these have been fully assigned to his institution, Stony Brook University, The State University of New York (SUNY). F Johnson is also listed as an inventor on several related patents, including CMC2.24, which have been fully assigned to Stony Brook University and to Chem-Master Int. Inc., on a shared basis. In addition, Traverse Biosciences Inc. has exclusively licensed patents from the Research Foundation for the State University of New York (RF/SUNY) covering the structure and use of the chemically-modified curcumins for the purpose of commercialization in human and animal health. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
